Dalba Got Back? Use of Dalbavancin for the Treatment of Vertebral Osteomyelitis.

Amber C StreifelLuke C StrnadMonica K SikkaCara D VarleyJina MakadiaEllie SukermanAlyse H DouglassHeather MayerKathleen YoungJames S Lewis

Published in: Open forum infectious diseases (2024)

Data evaluating dalbavancin use for vertebral osteomyelitis remain limited. In our retrospective cohort, 29 of 34 (85.3%) patients completed their dalbavancin course. Adverse reactions occurred for 6 (17.6%) and infection recurrence in 3 (8.8%) within 90 days. Dalbavancin appears to be safe and well-tolerated for vertebral osteomyelitis.

Keyphrases

bone mineral density
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
electronic health record
cross sectional
emergency department
body composition